patients

Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy

RIYADH, Saudi Arabia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has reinforced its…

2 weeks ago

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients

August 21, 2025 01:30 ET  | Source: NICOX SA Press Release Nicox Announces Positive Results from the NCX 470 Phase…

2 weeks ago

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight…

3 weeks ago

Brain Navi Biotechnology’s NaoTrac performs first surgeries in Spain

Brain Navi has officially landed in Spain! TAIPEI, Aug.11, 2025 /PRNewswire/ -- Such an achievement has been made possible through…

3 weeks ago

Manipal Hospitals Kolkata completes 50 successful TAVR cases

KOLKATA, India, Aug. 12, 2025 /PRNewswire/ -- Manipal Hospitals - EM Bypass (erstwhile Medica Superspecialty Hospital), Kolkata is thrilled to announce…

4 weeks ago

Anteris Announces Results for the Second Quarter of 2025

MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR,…

4 weeks ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

4 weeks ago

Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience

Everhope Oncology takes the anxiety out of cancer treatment — with zero wait time, 2X faster service, pre-booked diagnostics, and…

4 weeks ago

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA

AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…

1 month ago

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today…

1 month ago